Drug Trial Radar · NCT06589830
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
May 13, 2025
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Teligene USIndustry
- Sponsor type
- Industry
- Collaborators
- Suzhou Teligene Ltd.
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study evaluates TL938 alone or in combination with trastuzumab in patients with HER2-positive advanced colorectal cancer. Cohort 1 determines the recommended Phase 2 dose of TL938 with trastuzumab. Cohorts 2 and 3 evaluate the efficacy and safety of TL938 with trastuzumab or TL938 alone at that dose.
Conditions
- Colorectal Cancer Metastatic
- Advanced Colorectal Cancer
Interventions
TL938 CapsulesDrug
Oral administration
TrastuzumabDrug
Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity, maximum tolerated dose, and recommended phase 2 doseTime frame: Pre-dose up to approximately 24 months post-dose
- Objective Response Rate (ORR) by IRCTime frame: Pre-dose up to approximately 24 months post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.